News Headlines Article

FDA, drugmakers agree to extend user-fee plan
Modern Healthcare

The Food and Drug Administration has agreed to work toward faster, more predictable reviews of new prescription drugs in return for hundreds of millions of dollars in continuing fees from drugmakers, under a draft agreement unveiled by the agency. The deal comes after months of closed-door meetings between FDA and drug industry officials working to extend a 2-decade-old program that supplements the agency’s budget with company fees. The latest agreement would require the FDA to provide more frequent updates on the status of certain drug reviews.